135:@0.890196:0.957873:0.914705:0.957873:0.914705:0.938882:0.890196:0.938882:0.007325:0.008593:0.008591
5:@0.941813:0.435294:0.963291:0.435294:0.963291:0.387816:0.941813:0.387816:0.021478
OPTIMIZING NANOPORE SEQUENCING-BASED DETECTION OF STRUCTURAL VARIANTS ENABLES:@0.340931:0.057372:0.882352:0.057372:0.882352:0.040253:0.340931:0.040253:0.008442:0.007975:0.006387:0.003511:0.011112:0.003511:0.006630:0.003511:0.008759:0.008404:0.002988:0.008759:0.007919:0.008759:0.008442:0.008050:0.008442:0.008423:0.006985:0.002988:0.007807:0.006985:0.008442:0.008367:0.006985:0.008759:0.008255:0.003511:0.008759:0.008404:0.005155:0.008121:0.007713:0.007807:0.006985:0.008423:0.002988:0.008423:0.006985:0.006387:0.006985:0.008178:0.006387:0.003511:0.008442:0.008759:0.002988:0.008442:0.006593:0.002988:0.007732:0.006387:0.008367:0.008367:0.008180:0.006387:0.008367:0.008423:0.007919:0.006292:0.002801:0.006966:0.007919:0.008423:0.003511:0.007919:0.008759:0.006313:0.007807:0.002988:0.006985:0.008759:0.007919:0.008236:0.006481:0.006871:0.007807
INDIVIDUALIZED CIRCULATING TUMOR DNA-BASED DISEASE MONITORING IN CANCER PATIENTS:@0.337347:0.073247:0.882352:0.073247:0.882352:0.056128:0.337347:0.056128:0.003511:0.008759:0.008423:0.003511:0.007620:0.003511:0.008423:0.008253:0.007919:0.006481:0.003511:0.006630:0.006985:0.008423:0.002988:0.008255:0.003511:0.008309:0.008255:0.008367:0.006481:0.007097:0.006387:0.003511:0.008759:0.008404:0.002988:0.006387:0.008367:0.011112:0.008442:0.008423:0.002988:0.008423:0.008759:0.007543:0.005155:0.008124:0.007713:0.007807:0.006985:0.008423:0.002988:0.008423:0.003511:0.007807:0.006985:0.007713:0.007807:0.006985:0.002988:0.011112:0.008442:0.008759:0.003511:0.006311:0.008442:0.008423:0.003511:0.008759:0.008404:0.002988:0.003511:0.008759:0.002988:0.008178:0.007919:0.008759:0.008255:0.006985:0.008423:0.002988:0.007581:0.007099:0.006387:0.003511:0.006985:0.008759:0.006311:0.007807
Technologies). Thresholds for positive fluorescence were determined per primer pair :@0.147059:0.121273:0.886462:0.121273:0.886462:0.100900:0.147059:0.100900:0.010866:0.009108:0.008765:0.011459:0.011596:0.010934:0.005182:0.011048:0.009861:0.005547:0.009039:0.007670:0.006939:0.004497:0.007063:0.011470:0.011470:0.007442:0.009039:0.007556:0.011299:0.010934:0.005182:0.011391:0.007670:0.007065:0.006024:0.010845:0.007807:0.007063:0.011505:0.010957:0.007601:0.005273:0.006437:0.005547:0.009633:0.009039:0.007063:0.005638:0.005296:0.011345:0.010843:0.007442:0.009039:0.007875:0.008994:0.009039:0.011596:0.008994:0.009039:0.007065:0.014518:0.009039:0.007442:0.009039:0.007063:0.011322:0.009131:0.006209:0.009039:0.007807:0.017645:0.005615:0.011596:0.009108:0.011391:0.007063:0.011505:0.009039:0.007807:0.007063:0.011071:0.007807:0.005615:0.017485:0.009039:0.007807:0.007065:0.011365:0.009087:0.005615:0.007807:0.004109
based on positive and negative controls. Variant allele frequency (VAF) was calculated :@0.147059:0.141852:0.886555:0.141852:0.886555:0.121479:0.147059:0.121479:0.011117:0.009291:0.007875:0.009108:0.011391:0.005684:0.010843:0.011756:0.005684:0.011505:0.010957:0.007601:0.005273:0.006437:0.005547:0.009633:0.009039:0.005684:0.009085:0.011596:0.011391:0.005684:0.011596:0.009039:0.009861:0.008811:0.006437:0.005547:0.009633:0.009039:0.005684:0.008994:0.010843:0.011391:0.006437:0.007442:0.010934:0.005250:0.007670:0.004497:0.005684:0.012874:0.009085:0.007807:0.005798:0.009085:0.011391:0.006437:0.005684:0.009405:0.005385:0.005184:0.008948:0.005182:0.009039:0.005684:0.006414:0.007442:0.009108:0.010703:0.011347:0.009039:0.011596:0.009382:0.009724:0.005684:0.006825:0.012578:0.014929:0.011368:0.006939:0.005684:0.014723:0.009291:0.007670:0.005684:0.009108:0.009405:0.005182:0.009108:0.011550:0.005433:0.008811:0.006209:0.009108:0.011391:0.004109
according to the following formula: :@0.147059:0.162431:0.448484:0.162431:0.448484:0.142058:0.147059:0.142058:0.009291:0.008994:0.008994:0.010843:0.007442:0.011391:0.005615:0.011459:0.009861:0.004109:0.006209:0.011048:0.004109:0.006620:0.011299:0.009039:0.004109:0.006024:0.010936:0.005387:0.005182:0.010866:0.014723:0.005615:0.011457:0.009861:0.004109:0.006026:0.010843:0.007807:0.017280:0.011550:0.005433:0.009291:0.004497:0.004109
number of mutant molecules per µl in chip (as defined by Crystal Miner™ software) / :@0.147059:0.183009:0.886464:0.183009:0.886464:0.162636:0.147059:0.162636:0.011391:0.011413:0.017394:0.011254:0.009039:0.007807:0.006286:0.010843:0.006209:0.006289:0.017280:0.011071:0.006551:0.009085:0.011391:0.006437:0.006286:0.017485:0.010934:0.005182:0.009108:0.009108:0.011550:0.005182:0.009039:0.007670:0.006289:0.011502:0.009039:0.007807:0.006289:0.010957:0.005250:0.006286:0.005615:0.011756:0.006289:0.008765:0.011459:0.005271:0.011276:0.006289:0.006939:0.009291:0.007670:0.006286:0.011322:0.009039:0.005684:0.005684:0.011596:0.009108:0.011391:0.006286:0.010843:0.009724:0.006286:0.014611:0.008398:0.009724:0.007510:0.006551:0.009405:0.005250:0.006286:0.019426:0.005615:0.011596:0.009039:0.007807:0.007487:0.006289:0.007875:0.010843:0.006197:0.006197:0.014723:0.009085:0.007442:0.009039:0.006939:0.006286:0.007099:0.004109
(number of mutant molecules per µl in chip + number of wild-type molecules per µl in :@0.147059:0.203588:0.886395:0.203588:0.886395:0.183215:0.147059:0.183215:0.006939:0.011391:0.011413:0.017394:0.011254:0.009039:0.007807:0.004771:0.010843:0.006209:0.004771:0.017280:0.011071:0.006551:0.009085:0.011391:0.006437:0.004771:0.017485:0.010934:0.005182:0.009108:0.009108:0.011550:0.005182:0.009039:0.007670:0.004771:0.011505:0.009039:0.007807:0.004771:0.010957:0.005250:0.004771:0.005615:0.011756:0.004771:0.008765:0.011459:0.005273:0.011276:0.004771:0.011779:0.004771:0.011391:0.011413:0.017394:0.011254:0.009039:0.007807:0.004771:0.010843:0.006209:0.004771:0.014723:0.005752:0.005182:0.011391:0.007533:0.006437:0.009724:0.011505:0.009039:0.004771:0.017485:0.010934:0.005182:0.009108:0.009108:0.011550:0.005182:0.009039:0.007670:0.004771:0.011505:0.009039:0.007807:0.004771:0.010957:0.005250:0.004771:0.005615:0.011756:0.004109
chip) * 100%. :@0.147059:0.224167:0.262106:0.224167:0.262106:0.203794:0.147059:0.203794:0.008765:0.011459:0.005273:0.011276:0.006939:0.004109:0.008172:0.004109:0.010432:0.010432:0.010432:0.015043:0.004497:0.004109
Absolute number of mutant molecules per mL plasma was calculated as follows: :@0.147059:0.244745:0.821150:0.244745:0.821150:0.224373:0.147059:0.224373:0.014198:0.010934:0.007875:0.010934:0.004908:0.011071:0.006209:0.009039:0.004109:0.011391:0.011413:0.017394:0.011254:0.009039:0.007807:0.004109:0.010843:0.006209:0.004109:0.017278:0.011071:0.006551:0.009085:0.011391:0.006437:0.004109:0.017485:0.010934:0.005182:0.009108:0.009108:0.011550:0.005182:0.009039:0.007670:0.004109:0.011505:0.009039:0.007807:0.004109:0.017645:0.011619:0.004109:0.011160:0.005433:0.009291:0.007604:0.017577:0.009291:0.004109:0.014723:0.009291:0.007670:0.004109:0.009106:0.009405:0.005182:0.009108:0.011550:0.005433:0.008811:0.006209:0.009108:0.011391:0.004109:0.009291:0.007670:0.004109:0.006024:0.010934:0.005387:0.005182:0.010866:0.014723:0.007670:0.004497:0.004109
number of mutant molecules per µl in chip * 28 µl (input in chip) / (used eluate/total :@0.147059:0.265324:0.886573:0.265324:0.886573:0.244951:0.147059:0.244951:0.011391:0.011413:0.017394:0.011254:0.009039:0.007807:0.006049:0.010843:0.006209:0.006049:0.017280:0.011071:0.006551:0.009085:0.011391:0.006437:0.006049:0.017485:0.010934:0.005182:0.009108:0.009108:0.011550:0.005182:0.009039:0.007670:0.006049:0.011502:0.009039:0.007807:0.006049:0.010957:0.005250:0.006049:0.005615:0.011756:0.006049:0.008765:0.011459:0.005273:0.011276:0.006049:0.008172:0.006049:0.010432:0.010432:0.006049:0.010957:0.005250:0.006049:0.006939:0.005615:0.011391:0.011048:0.011071:0.006437:0.006049:0.005615:0.011756:0.006049:0.008765:0.011459:0.005273:0.011276:0.006939:0.006049:0.007099:0.006049:0.006939:0.011413:0.007873:0.009108:0.011391:0.006049:0.008948:0.004908:0.011596:0.008811:0.006209:0.009039:0.007099:0.006209:0.010820:0.006551:0.009405:0.005250:0.004109
volume of eluate * volume of plasma used for isolation). :@0.147059:0.285903:0.616261:0.285903:0.616261:0.265530:0.147059:0.265530:0.009633:0.010934:0.004908:0.011413:0.017485:0.009039:0.004109:0.010843:0.006209:0.004109:0.008948:0.004908:0.011596:0.008811:0.006209:0.009039:0.004109:0.008172:0.004109:0.009633:0.010934:0.004908:0.011413:0.017485:0.009039:0.004109:0.010843:0.006209:0.004109:0.011160:0.005433:0.009291:0.007604:0.017577:0.009291:0.004109:0.011413:0.007873:0.009108:0.011391:0.004109:0.006026:0.010843:0.007807:0.004109:0.005615:0.007875:0.010934:0.005433:0.008811:0.006437:0.005545:0.010845:0.011756:0.006939:0.004497:0.004109
To correct for zero values on a log scale, +1 was counted to every value and axes were :@0.147059:0.306482:0.886553:0.306482:0.886553:0.286109:0.147059:0.286109:0.010866:0.011048:0.005798:0.008994:0.010843:0.007807:0.007444:0.009106:0.009108:0.006437:0.005798:0.006026:0.010843:0.007807:0.005798:0.008834:0.009039:0.007442:0.011048:0.005798:0.009838:0.009405:0.004908:0.011345:0.009039:0.007670:0.005798:0.010843:0.011756:0.005798:0.009291:0.005798:0.005182:0.011048:0.009861:0.005798:0.007875:0.009108:0.009405:0.005182:0.008743:0.004497:0.005798:0.011779:0.010432:0.005798:0.014723:0.009291:0.007670:0.005798:0.008994:0.010820:0.011413:0.011391:0.006209:0.009108:0.011391:0.005798:0.006209:0.011048:0.005798:0.009336:0.009633:0.009039:0.008398:0.009724:0.005798:0.009838:0.009405:0.004908:0.011345:0.009039:0.005798:0.009085:0.011596:0.011391:0.005798:0.009291:0.009884:0.009039:0.007670:0.005798:0.014518:0.009039:0.007442:0.009039:0.004109
corrected with -1. Spearman’s correlation coefficient was calculated for comparisons of :@0.147059:0.327060:0.886551:0.327060:0.886551:0.306687:0.147059:0.306687:0.008994:0.010843:0.007807:0.007442:0.009108:0.009108:0.006209:0.009108:0.011391:0.005341:0.014723:0.005273:0.006617:0.011459:0.005341:0.007533:0.010432:0.004497:0.005341:0.009793:0.011505:0.009291:0.009085:0.007807:0.017577:0.009085:0.009587:0.001735:0.007670:0.005341:0.008994:0.010843:0.007807:0.007442:0.008948:0.005433:0.008811:0.006437:0.005547:0.010843:0.011756:0.005341:0.008994:0.011274:0.009039:0.005692:0.005692:0.005623:0.008994:0.005547:0.009039:0.011391:0.006437:0.005341:0.014723:0.009291:0.007670:0.005341:0.009108:0.009405:0.005182:0.009108:0.011550:0.005433:0.008811:0.006209:0.009108:0.011391:0.005341:0.006026:0.010843:0.007807:0.005341:0.008994:0.010843:0.017280:0.011368:0.009085:0.007807:0.005615:0.007875:0.010843:0.011619:0.007670:0.005341:0.010843:0.006209:0.004109
VAF based on upstream wild-type allele vs downstream wild-type allele, two replicates :@0.147059:0.347639:0.886366:0.347639:0.886366:0.327266:0.147059:0.327266:0.012578:0.014929:0.011276:0.005227:0.011117:0.009291:0.007873:0.009108:0.011391:0.005227:0.010843:0.011756:0.005227:0.011071:0.011185:0.007510:0.006437:0.007442:0.009291:0.009085:0.017645:0.005227:0.014723:0.005750:0.005182:0.011391:0.007533:0.006437:0.009724:0.011505:0.009039:0.005227:0.009405:0.005387:0.005182:0.008948:0.005182:0.009039:0.005227:0.009838:0.007670:0.005227:0.011322:0.010866:0.014723:0.011619:0.007510:0.006437:0.007442:0.009291:0.009085:0.017645:0.005227:0.014723:0.005752:0.005182:0.011391:0.007533:0.006437:0.009724:0.011505:0.009039:0.005227:0.009405:0.005387:0.005182:0.008948:0.005182:0.008743:0.004497:0.005227:0.006437:0.014518:0.011048:0.005227:0.007442:0.009128:0.011162:0.005250:0.005547:0.009108:0.008811:0.006209:0.009039:0.007670:0.004109
and pre-amplified vs non-pre-amplified cfDNA samples. Corresponding slope was cal-:@0.147059:0.368218:0.882353:0.368218:0.882353:0.347845:0.147059:0.347845:0.009085:0.011596:0.011391:0.004816:0.011071:0.007442:0.009039:0.007533:0.009085:0.017280:0.011162:0.005250:0.005615:0.005684:0.005615:0.009106:0.011391:0.004816:0.009838:0.007670:0.004816:0.011596:0.010843:0.011756:0.007533:0.011071:0.007442:0.009039:0.007533:0.009085:0.017280:0.011162:0.005250:0.005615:0.005684:0.005615:0.009106:0.011391:0.004816:0.008994:0.006209:0.015773:0.015408:0.014929:0.004816:0.007944:0.009087:0.017280:0.011160:0.005184:0.009039:0.007670:0.004497:0.004816:0.014997:0.010843:0.007807:0.007442:0.009039:0.007510:0.011505:0.010843:0.011596:0.011391:0.005615:0.011459:0.009861:0.004816:0.007556:0.005182:0.010820:0.011502:0.009039:0.004816:0.014723:0.009291:0.007670:0.004816:0.009108:0.009405:0.005184:0.007533
culated by using linear regression analysis.:@0.147059:0.388796:0.500940:0.388796:0.500940:0.368423:0.147059:0.368423:0.009108:0.011550:0.005433:0.008811:0.006209:0.009108:0.011391:0.004109:0.010840:0.009724:0.004109:0.011413:0.007601:0.005615:0.011459:0.009861:0.004109:0.005250:0.005615:0.011596:0.009291:0.009085:0.007807:0.004109:0.007442:0.009039:0.009861:0.007442:0.009039:0.007533:0.007601:0.005547:0.010843:0.011756:0.004109:0.009085:0.011687:0.009405:0.005182:0.009724:0.007601:0.005615:0.007670:0.004497
Declarations:@0.147059:0.461746:0.286277:0.461746:0.286277:0.433636:0.147059:0.433636:0.013103:0.011069:0.012841:0.010285:0.012318:0.013103:0.011040:0.010343:0.006217:0.013132:0.013626:0.012144
Ethics approval and consent to participate:@0.147059:0.507681:0.530444:0.507681:0.530444:0.484521:0.147059:0.484521:0.009363:0.008616:0.011579:0.004856:0.011007:0.010409:0.003733:0.010558:0.010733:0.010733:0.011081:0.011106:0.009288:0.010558:0.008442:0.003735:0.010558:0.011679:0.011231:0.003984:0.011007:0.011256:0.011679:0.010409:0.009363:0.011679:0.008367:0.003984:0.008516:0.011256:0.003984:0.010108:0.010558:0.011081:0.008616:0.004856:0.011007:0.004856:0.010110:0.009463:0.008616:0.009363
Tumor samples of four patients with high-grade serous ovarian cancer (OC) and six pa-:@0.147059:0.549604:0.882353:0.549604:0.882353:0.529231:0.147059:0.529231:0.010911:0.011413:0.017485:0.010843:0.007807:0.004246:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.004246:0.010843:0.006209:0.004246:0.006026:0.010820:0.011413:0.007807:0.004246:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004246:0.014723:0.005271:0.006620:0.011459:0.004246:0.011459:0.005615:0.009930:0.011459:0.007533:0.009861:0.007896:0.009291:0.011322:0.009039:0.004246:0.007875:0.009039:0.007442:0.010820:0.011413:0.007670:0.004246:0.010866:0.009838:0.009085:0.007807:0.005798:0.009085:0.011756:0.004246:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.004246:0.006939:0.016778:0.014678:0.006939:0.004246:0.009085:0.011596:0.011391:0.004246:0.007601:0.005615:0.010089:0.004246:0.011368:0.009247:0.007533
tients with metastatic castration resistant prostate cancer (PC) were used in this study. :@0.147059:0.570183:0.886462:0.570183:0.886462:0.549810:0.147059:0.549810:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.005730:0.014723:0.005273:0.006620:0.011459:0.005730:0.017485:0.009131:0.006551:0.009291:0.007510:0.006551:0.008811:0.006437:0.005547:0.008994:0.005730:0.009106:0.009291:0.007512:0.006437:0.007896:0.008811:0.006437:0.005547:0.010843:0.011756:0.005730:0.007442:0.009039:0.007601:0.005615:0.007512:0.006549:0.009085:0.011391:0.006437:0.005730:0.011071:0.007442:0.010957:0.007510:0.006551:0.008811:0.006209:0.009039:0.005730:0.009106:0.009087:0.011596:0.008994:0.009039:0.007807:0.005730:0.006939:0.012167:0.014678:0.006939:0.005730:0.014518:0.009039:0.007442:0.009039:0.005730:0.011413:0.007875:0.009108:0.011391:0.005730:0.005615:0.011756:0.005730:0.006620:0.011459:0.005615:0.007670:0.005730:0.007510:0.006163:0.011345:0.011322:0.007989:0.004497:0.004109
Patients with OC participated in the HUB-OVI study, in which tumor tissue and blood :@0.147059:0.590762:0.886539:0.590762:0.886539:0.570389:0.147059:0.570389:0.011413:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004622:0.014723:0.005273:0.006620:0.011459:0.004634:0.016775:0.014678:0.004634:0.011368:0.009085:0.007967:0.006437:0.005547:0.008994:0.005273:0.011365:0.008811:0.006209:0.009108:0.011391:0.004634:0.005615:0.011756:0.004622:0.006620:0.011299:0.009039:0.004634:0.016846:0.016024:0.012646:0.007533:0.016113:0.015089:0.007259:0.004634:0.007510:0.006163:0.011345:0.011322:0.007989:0.004497:0.004622:0.005615:0.011756:0.004634:0.014792:0.011459:0.005547:0.008765:0.011459:0.004622:0.006163:0.011413:0.017485:0.010843:0.007807:0.004634:0.006437:0.005615:0.007535:0.007510:0.011345:0.009039:0.004622:0.009085:0.011596:0.011391:0.004634:0.010911:0.005182:0.011276:0.011276:0.011391:0.004109
were obtained for organoid culture (tumor) and whole genome sequencing (WGS) (tu-:@0.147059:0.611340:0.882353:0.611340:0.882353:0.590967:0.147059:0.590967:0.014518:0.009039:0.007442:0.009039:0.004816:0.010957:0.010797:0.006549:0.009085:0.005615:0.011598:0.009106:0.011391:0.004816:0.006026:0.010843:0.007807:0.004816:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.004816:0.009108:0.011550:0.004908:0.006163:0.011413:0.007442:0.009039:0.004816:0.006939:0.006163:0.011413:0.017485:0.010843:0.007807:0.006939:0.004816:0.009085:0.011596:0.011391:0.004816:0.014792:0.011299:0.010934:0.005182:0.009039:0.004816:0.009658:0.009039:0.011596:0.010843:0.017485:0.009039:0.004816:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.004816:0.006825:0.020270:0.015682:0.010112:0.006939:0.004816:0.006939:0.006163:0.011457:0.007533
mor and blood). Clinical data was extracted from the patient file in collaboration with :@0.147059:0.631919:0.886546:0.631919:0.886546:0.611546:0.147059:0.611546:0.017485:0.010843:0.007807:0.005364:0.009085:0.011596:0.011391:0.005364:0.010909:0.005182:0.011276:0.011276:0.011391:0.006939:0.004497:0.005364:0.014746:0.005250:0.005615:0.011756:0.005547:0.009108:0.009402:0.005250:0.005364:0.011571:0.008813:0.006549:0.009291:0.005364:0.014723:0.009291:0.007670:0.005364:0.009106:0.010089:0.006437:0.007898:0.009291:0.009108:0.006209:0.009108:0.011391:0.005364:0.006414:0.007442:0.010843:0.017645:0.005364:0.006620:0.011299:0.009039:0.005364:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.005364:0.005684:0.005821:0.005182:0.009039:0.005364:0.005615:0.011756:0.005364:0.008994:0.010934:0.005387:0.005433:0.009108:0.011254:0.010843:0.007898:0.008811:0.006437:0.005547:0.010843:0.011756:0.005364:0.014723:0.005273:0.006620:0.011459:0.004109
the Dutch Cancer Registration. Patients with PC participated in both the CPCT-02 study :@0.147059:0.652498:0.886510:0.652498:0.886510:0.632125:0.147059:0.632125:0.006620:0.011299:0.009039:0.003310:0.016230:0.011071:0.006209:0.008765:0.011459:0.003310:0.014974:0.009085:0.011596:0.008994:0.009039:0.007807:0.003310:0.013696:0.009039:0.009861:0.005615:0.007510:0.006437:0.007898:0.008811:0.006437:0.005547:0.010843:0.011756:0.004497:0.003310:0.011413:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.003310:0.014723:0.005273:0.006620:0.011459:0.003310:0.012167:0.014678:0.003310:0.011368:0.009085:0.007967:0.006437:0.005547:0.008994:0.005273:0.011368:0.008811:0.006209:0.009108:0.011391:0.003310:0.005615:0.011756:0.003310:0.011254:0.010820:0.006620:0.011459:0.003310:0.006620:0.011299:0.009039:0.003310:0.014678:0.012167:0.014678:0.011801:0.007533:0.010432:0.010432:0.003310:0.007510:0.006163:0.011345:0.011322:0.009724:0.004109
(NCT01855477) and the CIRCUS study (NTR5732), in which tumor tissue from a met-:@0.147059:0.673076:0.882353:0.673076:0.882353:0.652704:0.147059:0.652704:0.006939:0.015887:0.014678:0.013354:0.010432:0.010432:0.010432:0.010432:0.010432:0.010432:0.010432:0.010432:0.006939:0.003915:0.009085:0.011596:0.011391:0.003926:0.006620:0.011299:0.009039:0.003926:0.014678:0.007259:0.013308:0.014678:0.016024:0.010112:0.003926:0.007512:0.006161:0.011347:0.011322:0.009724:0.003926:0.006939:0.016230:0.013354:0.013376:0.010432:0.010432:0.010432:0.010432:0.006939:0.004497:0.003926:0.005615:0.011756:0.003926:0.014792:0.011459:0.005545:0.008768:0.011459:0.003926:0.006163:0.011413:0.017485:0.010843:0.007807:0.003926:0.006437:0.005615:0.007533:0.007510:0.011345:0.009039:0.003926:0.006414:0.007442:0.010843:0.017645:0.003926:0.009291:0.003926:0.017485:0.009131:0.006353:0.007533
astatic lesion for WGS and longitudinal cfDNA samples were obtained. Longitudinal :@0.147059:0.693655:0.886507:0.693655:0.886507:0.673282:0.147059:0.673282:0.009291:0.007510:0.006551:0.008811:0.006437:0.005547:0.008994:0.006780:0.005182:0.009039:0.007601:0.005547:0.010843:0.011756:0.006780:0.006026:0.010843:0.007807:0.006780:0.020270:0.015682:0.010112:0.006780:0.009085:0.011596:0.011391:0.006780:0.005182:0.010843:0.011459:0.009861:0.005273:0.006163:0.011345:0.011391:0.005615:0.011687:0.009405:0.005250:0.006780:0.008994:0.006209:0.015771:0.015408:0.014929:0.006780:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.006780:0.014518:0.009039:0.007442:0.009039:0.006780:0.010957:0.010797:0.006551:0.009085:0.005615:0.011596:0.009108:0.011117:0.004497:0.006780:0.011824:0.010843:0.011459:0.009861:0.005273:0.006163:0.011345:0.011391:0.005615:0.011687:0.009405:0.005250:0.004109
ctDNA quantification was performed for four patients with PC. Informed consent was :@0.147059:0.714234:0.886437:0.714234:0.886437:0.693861:0.147059:0.693861:0.009108:0.006437:0.015773:0.015408:0.014929:0.005113:0.010706:0.011596:0.009085:0.011391:0.006437:0.005615:0.005684:0.005615:0.009106:0.008811:0.006437:0.005547:0.010843:0.011756:0.005113:0.014723:0.009291:0.007670:0.005113:0.011505:0.009039:0.007807:0.006026:0.010843:0.007807:0.017485:0.009108:0.011391:0.005113:0.006026:0.010843:0.007807:0.005113:0.006026:0.010820:0.011413:0.007807:0.005113:0.011365:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.005113:0.014723:0.005273:0.006620:0.011459:0.005113:0.012167:0.014678:0.004497:0.005113:0.006894:0.011756:0.006026:0.010843:0.007807:0.017485:0.009108:0.011391:0.005113:0.008994:0.010843:0.011619:0.007875:0.009039:0.011391:0.006437:0.005113:0.014723:0.009291:0.007670:0.004109
obtained within all studies. Clinical data for patients with PC were collected in an elec-:@0.147059:0.734813:0.882353:0.734813:0.882353:0.714440:0.147059:0.714440:0.010957:0.010797:0.006551:0.009085:0.005615:0.011596:0.009108:0.011391:0.004931:0.014723:0.005273:0.006620:0.011459:0.005615:0.011756:0.004931:0.009405:0.005387:0.005250:0.004931:0.007510:0.006163:0.011345:0.011391:0.005547:0.009039:0.007670:0.004497:0.004931:0.014744:0.005250:0.005615:0.011756:0.005547:0.009108:0.009405:0.005250:0.004931:0.011573:0.008811:0.006551:0.009291:0.004931:0.006026:0.010843:0.007807:0.004931:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004931:0.014723:0.005273:0.006620:0.011459:0.004931:0.012167:0.014678:0.004931:0.014518:0.009039:0.007442:0.009039:0.004931:0.008994:0.010934:0.005387:0.005182:0.009108:0.009108:0.006209:0.009108:0.011391:0.004931:0.005615:0.011756:0.004931:0.009085:0.011756:0.004931:0.008948:0.005182:0.009108:0.008880:0.007533
tronic case report form (ALEA Clinical). All studies were performed according to the :@0.147059:0.755391:0.886505:0.755391:0.886505:0.735018:0.147059:0.735018:0.006437:0.007442:0.010843:0.011756:0.005547:0.008994:0.005935:0.009108:0.009291:0.007875:0.009039:0.005935:0.007442:0.009131:0.011502:0.010843:0.007967:0.006437:0.005935:0.006026:0.010843:0.007807:0.017645:0.005935:0.006939:0.014929:0.011619:0.012098:0.014929:0.005935:0.014746:0.005250:0.005615:0.011756:0.005547:0.009108:0.009402:0.005250:0.006939:0.004497:0.005935:0.015066:0.005387:0.005250:0.005935:0.007510:0.006163:0.011345:0.011391:0.005547:0.009039:0.007670:0.005935:0.014518:0.009039:0.007442:0.009039:0.005935:0.011505:0.009039:0.007807:0.006024:0.010845:0.007807:0.017488:0.009106:0.011391:0.005935:0.009291:0.008994:0.008994:0.010843:0.007442:0.011391:0.005615:0.011459:0.009861:0.005935:0.006209:0.011048:0.005935:0.006620:0.011299:0.009039:0.004109
guidelines of the European Network of Research Ethics Committees (EUREC) following :@0.147059:0.775970:0.886505:0.775970:0.886505:0.755597:0.147059:0.755597:0.009861:0.011413:0.005547:0.011322:0.008948:0.005250:0.005615:0.011596:0.009039:0.007670:0.003538:0.010843:0.006209:0.003538:0.006620:0.011299:0.009039:0.003538:0.011505:0.011413:0.007442:0.010820:0.011505:0.009288:0.009087:0.011756:0.003538:0.015522:0.009131:0.006437:0.014518:0.010843:0.007601:0.010523:0.003538:0.010843:0.006209:0.003538:0.013696:0.009039:0.007873:0.009291:0.009085:0.007442:0.008765:0.011459:0.003538:0.011507:0.006617:0.011459:0.005547:0.008994:0.007670:0.003538:0.014997:0.010843:0.017645:0.017645:0.005273:0.006163:0.006209:0.009108:0.009039:0.007670:0.003538:0.006939:0.012098:0.016024:0.013376:0.012098:0.014678:0.006939:0.003538:0.006024:0.010934:0.005387:0.005182:0.010866:0.014723:0.005615:0.011459:0.009861:0.004109
European, national and local law.:@0.147059:0.796549:0.424607:0.796549:0.424607:0.776176:0.147059:0.776176:0.011505:0.011413:0.007442:0.010820:0.011505:0.009291:0.009085:0.011756:0.004497:0.004109:0.011687:0.008811:0.006437:0.005547:0.010843:0.011687:0.009405:0.005250:0.004109:0.009085:0.011596:0.011391:0.004109:0.005182:0.011276:0.009108:0.009402:0.005250:0.004109:0.005433:0.008925:0.012988:0.004497
Consent for publication:@0.147059:0.850463:0.363305:0.850463:0.363305:0.827304:0.147059:0.827304:0.011007:0.011256:0.011679:0.010409:0.009363:0.011679:0.008367:0.003984:0.008840:0.011256:0.011231:0.003984:0.010733:0.011156:0.010982:0.008691:0.004856:0.010905:0.009463:0.008616:0.004856:0.011256:0.011679
Not applicable.:@0.147059:0.892387:0.273311:0.892387:0.273311:0.872014:0.147059:0.872014:0.015522:0.010820:0.006437:0.004109:0.008811:0.011048:0.011162:0.005248:0.005547:0.009108:0.009108:0.010911:0.005182:0.008743:0.004497